Navigation Links
Oncolytics Biotech(R) Inc. Completes Enrolment in Combination REOLYSIN(R)/Gemcitabine Trial
Date:3/25/2009

h and development projects, the efficacy of REOLYSIN as a cancer treatment, the tolerability of REOLYSIN outside a controlled test, the success and timely completion of clinical studies and trials, the Company's ability to successfully commercialize REOLYSIN, uncertainties related to the research and development of pharmaceuticals and uncertainties related to the regulatory process. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned against placing undue reliance on forward-looking statements. The Company does not undertake to update these forward-looking statements, except as required by applicable laws.


'/>"/>
SOURCE Oncolytics Biotech Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Oncolytics Biotech(R) Inc. Collaborators Present Reovirus Research at Replicating Oncolytic Virus Meeting
2. Oncolytics Biotech(R) Inc. Collaborators Present Positive Head and Neck Results in Phase I/II Combination REOLYSIN(R) and Paclitaxel/Carboplatin Trial
3. Oncolytics Biotech(R) Inc. Collaborators Update Combination REOLYSIN(R) and Docetaxel Trial Results at Replicating Oncolytic Virus Meeting
4. Oncolytics Biotech(R) Inc. Announces Reovirus Research to be Presented at AACR Annual Meeting
5. Oncolytics Biotech(R) Inc. Reports Highlights and Financial Results for 2008
6. Media Advisory - Oncolytics Biotech(R) Inc. to Present at BioPartnering North America
7. Oncolytics Biotech Inc. Announces Issuance of 31st U.S. Patent
8. Oncolytics Biotech Inc.s REOLYSIN(R) Exceeds Primary Statistical Endpoint in U.S. Phase 2 Sarcoma Study
9. Media Advisory - Oncolytics Biotech Inc. to Present at Rodman & Renshaw 10th Annual Healthcare Conference
10. Oncolytics Biotech Inc. Investigators Present Interim U.S. REOLYSIN(R) Phase II Sarcoma Trial Data
11. Oncolytics Biotech Inc. Announces U.S. Phase II Sarcoma Clinical Trial Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... The 6th Annual Arrowhead Personalized ... October 29-30 in San Francisco, CA. This year’s conference ... researchers and clinicians focused on addressing and solving the ... the twelve years since the sequencing of the human ... with pharmacogenetic information in the label and molecular diagnostics ...
(Date:8/20/2014)... improve the health of your heart, researchers have discovered. ... a standard TENS machine like those designed to relieve ... the small raised flap at the front of the ... The stimulation changed the influence of the nervous system ... can drive failing hearts too hard. , Professor Jim ...
(Date:8/19/2014)... Piscataway, NJ (PRWEB) August 20, 2014 ... engineering and regenerative medicine is an inadequate vascular ... engineered constructs and decellularized tissues is critical for ... Researchers have attempted to mitigate deficiencies in vascularization ... including adding scaffold bioactivity, optimizing scaffold design and ...
(Date:8/19/2014)... , Aug. 19, 2014 A Geisinger ... been nominated for a Centers for Disease Control and ... a major public health concern. Joseph ... is one of a team of researchers nominated for ... C. Shepard Science Award for Data Methods and Study ...
Breaking Biology Technology:6th Annual Personalized and Precision Medicine Conference Bringing Together Thought Leaders to Discuss Clinical Implementation, Dx Reimbursement, Big Data, and Sequencing 2'Tickling' your ear could be good for your heart 2Vascularization in Tissue Engineering Highlighted at 12th New Jersey Symposium on Biomaterials Science 2Geisinger investigator nominated for federal award 2Geisinger investigator nominated for federal award 3
... Increase 53% and 52% Respectively ... ... CLRT ), a premier technology and services resource for,pathologists, oncologists and ... year ended December 31, 2007.,Revenue from continuing operations was $12.4 million ...
... ... presentations, SOUTH SAN FRANCISCO, Calif., March 31 ,Exelixis, Inc. ... company,s investigational compounds XL647, XL184, XL765 and,XL880 will be presented at the ... from May 30 to June 3, 2008 in,Chicago, Illinois. The clinical trial ...
... Medarex, Inc.,(Nasdaq: MEDX ) today announced ... undisclosed amount from its licensing partner, Novo Nordisk ... of an Investigational New Drug,application by Novo Nordisk ... Medarex,s UltiMAb(R) technology. Medarex may receive future,milestone payments ...
Cached Biology Technology:Clarient Announces Fourth Quarter and Year-End 2007 Financial Results 2Clarient Announces Fourth Quarter and Year-End 2007 Financial Results 3Clarient Announces Fourth Quarter and Year-End 2007 Financial Results 4Clarient Announces Fourth Quarter and Year-End 2007 Financial Results 5Clarient Announces Fourth Quarter and Year-End 2007 Financial Results 6Clarient Announces Fourth Quarter and Year-End 2007 Financial Results 7Clarient Announces Fourth Quarter and Year-End 2007 Financial Results 8Clarient Announces Fourth Quarter and Year-End 2007 Financial Results 9Seven Abstracts Featuring Exelixis Compounds Accepted for Presentation at 2008 ASCO Annual Meeting 2Medarex to Receive Milestone Payment from Novo Nordisk 2
(Date:8/21/2014)... have developed a novel and versatile modeling strategy to ... new materials as well as for studying polyelectrolytes, including ... to model much larger and more complex polyelectrolyte systems, ... Li, lead author of a paper on the work ... Materials Science and Engineering. "This is a big step ...
(Date:8/20/2014)... a John and Rebecca Moores Professor of Biology and Biochemistry ... in the International Society for the Study of the Origin ... members two from the U.S., one from France and ... are elected every three years, and 36 have been named ... 20 countries, the ISSOL includes researchers from disciplines as varied ...
(Date:8/20/2014)... LAKE CITY Researchers at Huntsman Cancer Institute (HCI) at ... forms of the gene that encodes BCR-ABL, the unregulated ... According to the American Cancer Society, nearly 6,000 new ... Drugs already in use, called tyrosine kinase inhibitors (TKIs), ... They do not cure CML but control it in ...
Breaking Biology News(10 mins):Researchers develop models to study polyelectrolytes, including DNA and RNA 2UH professor named fellow by International Astrobiology Society 2Blueprint for next generation of chronic myeloid leukemia treatment 2
... for Free-Electron Laser Science have devised a novel way to boil ... concept, which has not yet been demonstrated in practice, could heat ... Celsius in just half a picosecond (a trillionth of a second). ... one picosecond is to a second what one second is to ...
... like Alzheimer,s, Parkinson,s and Creutzfeldt-Jakob disease. But amyloid ... the development of new composite materials for the ... even make objects invisible. Researchers from Chalmers ... about amyloid in an article published in the ...
... Caribou in southern and eastern Canada may disappear from most ... takes the toll on their habitat that scientists predict in ... Nature Climate Change . Scientists looked at reservoirs of ... to stable habitats. They found that caribou populations in the ...
Cached Biology News:Ultrafast heating of water -- This pot boils faster than you can watch it 2Ultrafast heating of water -- This pot boils faster than you can watch it 3Alzheimer substance may be the nanomaterial of tomorrow 2Climate change threatens genetic diversity, future of world's caribou 2
... (RNase III) from E. coli is an ... to dsRNA fragments that have 2-base, 3'-overhangs. ... dsRNA fragments of 12-15 bp. RNase ... canonical ribonucleotides as well as DuraScript™ RNA, ...
...
...
... to CRF The antibody ... CRF sequence that it was ... are found in the paraventricular ... in colchicine treated 4% FA ...
Biology Products: